Therapeutic antibody discovery and design

DJS Antibodies is pioneering advancements in the field of antibody therapeutics, particularly targeting chronic inflammatory diseases, which are a leading cause of mortality worldwide. The company has developed a proprietary platform known as HEPTAD, which focuses on the discovery of functional antibodies specifically targeting G protein-coupled receptors (GPCRs). This innovative approach aims to create precision medicines that address the limitations of traditional steroid-based treatments and existing biologics, which often have significant side effects. By leveraging a deep understanding of immunology, DJS Antibodies is positioned to develop highly specific biologics that can effectively target disease-causing pathways, thereby improving treatment outcomes for patients.

The company’s lead programs, DJS 002 and DJS 001, exemplify its commitment to revolutionizing treatment options for fibrotic diseases and myeloid cell-driven inflammatory conditions, respectively. DJS 002 targets a validated GPCR associated with fibrotic diseases, promising a well-tolerated and effective treatment option where current therapies fall short. Meanwhile, DJS 001 represents a first-in-class approach to addressing myeloid cell-driven inflammatory diseases, utilizing novel biological insights to achieve efficacy where competitors have failed. Through these initiatives, DJS Antibodies aims to deliver groundbreaking therapeutics that significantly enhance patient care in the realm of chronic inflammatory diseases.

United Kingdom

DJS Antibodies acquired by Abbvie (10/20/22)

DJS Antibodies was founded upon a vision of creating the next generation of antibody therapeutics. The company is dedicated to developing novel therapeutics to treat chronic inflammatory diseases through the discovery and development of antibodies.

DJS Antibodies

Company Details